SOPHiA GENETICS (NASDAQ:SOPH) Issues Earnings Results, Misses Expectations By $0.04 EPS

SOPHiA GENETICS (NASDAQ:SOPH) posted its quarterly earnings results on Tuesday. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04), Zacks reports. SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%.

Here are the key takeaways from SOPHiA GENETICS’s conference call:

• Q1 results — revenue of $21.7M (+22% YoY), a record 108,000 genomic analyses, and a 75.4% adjusted gross margin, which management says demonstrates the platform’s scalability.
• Network and retention — 537 institutional customers across 75 countries and ~2.5M profiles since inception; net dollar retention rose to 117% with multiple >$1M ACV expansion deals, supporting in-account upsell momentum.
• Biopharma traction — accelerating engagement with partners including AstraZeneca and J&J, plus efforts to build a global CDx and real-world evidence offering that management expects will be a material growth driver.
• Outlook and profitability path — the company reaffirmed 2026 revenue guidance of $92–$94M (20–22% growth) and adjusted EBITDA loss guidance of $29–$32M, and expects to approach adjusted-EBITDA breakeven by end-2026 and turn positive in H2 2027.
• Risks and headwinds — ongoing Guardant patent litigation (Q1 legal expense ~$1.4M, net ~$700k after interim recoveries), Swiss franc FX translation pressure raising dollar-reported costs, softness in Latin America, and elevated Q1 cash burn of $19.5M despite $65.4M cash on hand.

SOPHiA GENETICS Stock Performance

SOPH traded down $0.14 during midday trading on Tuesday, hitting $5.15. 46,688 shares of the company traded hands, compared to its average volume of 166,283. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01. The firm has a market capitalization of $352.72 million, a PE ratio of -10.10 and a beta of 1.01. The company’s 50-day moving average is $4.81 and its 200 day moving average is $4.78. SOPHiA GENETICS has a 52 week low of $2.59 and a 52 week high of $5.70.

Wall Street Analyst Weigh In

SOPH has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. Guggenheim increased their price objective on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, BTIG Research increased their price objective on shares of SOPHiA GENETICS from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, April 15th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $7.50.

Insider Transactions at SOPHiA GENETICS

In other SOPHiA GENETICS news, CEO Jurgi Camblong sold 43,129 shares of the company’s stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $4.96, for a total transaction of $213,919.84. Following the transaction, the chief executive officer owned 3,664,440 shares in the company, valued at approximately $18,175,622.40. This represents a 1.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 193,859 shares of company stock worth $943,777. 4.88% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On SOPHiA GENETICS

Several institutional investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP lifted its stake in shares of SOPHiA GENETICS by 24.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after purchasing an additional 6,205 shares during the period. Squarepoint Ops LLC bought a new position in shares of SOPHiA GENETICS in the 3rd quarter worth approximately $49,000. Quadrature Capital Ltd bought a new position in shares of SOPHiA GENETICS in the 4th quarter worth approximately $54,000. XTX Topco Ltd bought a new position in shares of SOPHiA GENETICS in the 4th quarter worth approximately $55,000. Finally, Archon Capital Management LLC lifted its stake in shares of SOPHiA GENETICS by 3.4% in the 4th quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock worth $2,061,000 after purchasing an additional 14,342 shares during the period. Institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.